COCP - Cocrystal Pharma plans to initiate a phase 1 trial of CC-42344 in Q3 2021

Cocrystal Pharma (COCP) announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in Q3 2021. “The planned Phase 1 study with CC-42344 will be conducted in Australia, which offers favorable regulatory policies and a clinical trial environment that aligns with our strategy for quickly and cost-efficiently moving into clinical development,” said James Martin, Cocrystal’s CFO and interim co-CEO.

For further details see:

Cocrystal Pharma plans to initiate a phase 1 trial of CC-42344 in Q3 2021